Cancer Antigen 19-9
The assay is indicated for the serial measurement of CA 19‑9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19‑9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.
Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. CA 19-9 cannot be used for early detection of pancreatic carcinoma. As the mucin is excreted exclusively via the liver, even a slight cholestasis can lead to clearly elevated CA 19-9 serum levels in some cases.
Gross hemolysis, Gross Lipemia
Room Temperature: 5 days Refrigerated: 3 weeks Frozen: 8 months
Cancer Antigen 19-9; CA 19-9; Carbohydrate antigen 19-9; CA 19-9 (Carbohydrate Antigen 19-9); Cancer Antigen 19-9 (CA 19-9); GI Cancer antigen
Serum, gel separator, SST
0 - 999